Evaluación retrospectiva de la efectividad y seguridad de cinacalcet para el tratamiento de hiperparatiroidismo secundario dependiendo del valor basal de paratohormona intacta

Objective: Cinacalcet is a calcimimetic agent, recommended for treating refractory secondary hyperparathyroidism in patients undergoing dialysis. The aim of this study was to evaluate the efficacy and safety of cinacalcet, comparing patients with baseline iPTH > 300 pg/ml with those with iPTH 300 pg/ml and 11 with iPTH 30%. The safety was evaluated based on the most frequent adverse effects and the levels of serum calcium 300 had significant differences before and after cinacalcet treatment in iPTH (563.49 + 286.88 pg/ml vs 315.15 + 201.948 pg/ml; P = .017) and serum calcium (9.1 + 1.77 mg/dl vs 8.15 + 1.2 mg/dl; P = .02). There were no significant differences in patients with initial iPTH 300pg/ml, and only in 27.3% of those with basal iPTH 300 pg/ml.